← Back to Knowledge Base

Primary topic: HSD17B13 gene cholesterol and blood-fat handling

HSD17B13 Gene and Metabolism: What It Can Mean in a Pathway Report

HSD17B13 is tracked because it connects to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. The current evidence index links this gene to Lipids with 1 SNP and 1 curated claim.

What is the HSD17B13 gene?

Hepatic lipid-droplet short-chain dehydrogenase/reductase with retinol dehydrogenase activity and liver lipid-droplet biology.

How HSD17B13 affects metabolism

When HSD17B13-related function is shifted, the practical effect is interpreted through lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. This does not mean the pathway is active or impaired right now; it means the gene can help prioritize what to check next.

What happens when HSD17B13 is altered

Altered HSD17B13 signal should be treated as a DNA-based tendency, not a diagnosis. 1 claim currently passes the report-use gate. The useful question is whether symptoms, labs, and lifestyle context line up with the pathway signal.

Curated SNP evidence for HSD17B13

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Evidence-backed report connection

HSD17B13 currently has 1 curated SNPs, 1 claim-level scores, and 1 claims eligible for pathway scoring.

Open the sample report
rs72613567HSD17B13 TA splice insertion1 claims · 2 study rows

enzyme activity · TA insertion

HSD17B13 lipid-droplet retinol dehydrogenase activity

Strong

rs72613567 TA insertion in HSD17B13 is associated with lower lipid-droplet retinol dehydrogenase activity.

HSD17B13 rs72613567:TA is staged as a loss-of-function lipid-droplet enzyme allele relevant to hepatic lipid/retinoid handling.

Likely effectLower enzyme activity signal
Signal sizeSmall signal
Evidence supportStrong support
Report useIncluded in pathway scoring
Show study evidence

Common symptoms people report

  • unexpected cholesterol or triglyceride results
  • family context around lipid markers
  • unclear ApoB, LDL-C, HDL-C, or triglyceride patterns

Biomarkers to validate

ApoB

Shows the number of atherogenic particles more directly than total cholesterol.

LDL-C, HDL-C, and triglycerides

Gives the basic lipid pattern that DNA can help contextualize.

Lp(a) or liver enzymes when relevant

Adds context for inherited lipid risk or liver lipid handling.

Where DNA analysis helps

DNA helps decide whether HSD17B13 deserves attention inside the broader Lipids pathway. It is most useful when combined with biomarkers instead of used as a standalone answer.

Example interpretation

HSD17B13 may add context to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling, especially when its SNP evidence lines up with other genes in the same pathway.

Suggested validation: ApoB.

What to do next

  • Review the Lipids pathway result before interpreting HSD17B13 on its own.
  • Use relevant biomarkers to confirm whether this DNA tendency is visible in current biology.
  • Treat supplement or nutrition decisions as follow-up steps only after the pattern fits symptoms or labs.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages